Over the past 20 years, therapies based on incretin hormones, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have become the preferred treatment for T2DM and obesity due to their efficacy and safety in numerous clinical trials [2,3,4]. The gene discussed is GLP1R; the disease is obesity disorder.